Hearticellgram®-AMI, mesenchymal stem cells for acute myocardial infarction
Hearticellgram®-AMI are bone marrow-derived mesenchymal stem cells (MSCs) used to treat acute myocardial infarction through intracorononary injection. This study assessed the safety and efficacy of intracoronary autologous transplantation of bone marrow-derived human MSCs in patients with acute myocardial infarction.
There were no adverse reactions or major cardiac events. There was an improvement in left ventricular ejection fraction, already evident 6hrs after treatment, in acute myocardial function patients who underwent percutaneous transluminal coronary angiography within 72 hrs of chest pain onset.
Read More
This was the first licensed stem cell treatment to use bone marrow–derived stem cells to treat diseases outside of the blood and immune systems. The approval was by the Korean FDA.
Read More
Product Information for
Hearticellgram®-AMI, mesenchymal stem cells for acute myocardial infarction
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access